行情

IMUC

IMUC

IMMUNOCELLULAR
OTCPK
0.830
+0.130
+18.57%
已收盘, 15:50 09/29 EDT
开盘
0.700
昨收
0.700
最高
0.840
最低
0.700
成交量
4,550
成交额
3,546
52周最高
0.840
52周最低
0.140
市值
9,401.47万
市盈率(TTM)
-19.0805
分时
5日
1月
3月
1年
5年
暂无数据
IMUC 简况
ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company's cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing. In addition, the Company also has a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. Its other product candidates are ICT-140 and ICT-121. ICT-107 is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. ICT-140 is a DC vaccine that targets over seven tumor-associated antigens expressed on ovarian cancer cells. It is developing ICT-121, a dendritic cell (DC)-based vaccine targeting CD133+ CSCs for the treatment of recurrent GBM and other solid tumor cancers, including ovarian, pancreatic and breast cancers.

微牛提供ImmunoCellular Therapeutics Ltd(OTCPK-IMUC)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的IMUC股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易IMUC股票基本功能。